broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K15600710-066-05-8 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.214619 | 4.646996 | 0.584974 | 0.763652 | 0.529307 | 0.597196 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000948 |
BRD-K16730910-001-10-7 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.970821 | 0.10904 | -0.009547 | 0.984921 | 0.041598 | null | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000948 |
BRD-K17555800-003-02-3 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.389567 | -0.693962 | 0.162671 | 0.920598 | 0.000996 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000948 |
BRD-K17610631-001-03-3 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 2.194069 | 3.060657 | 0.726599 | 1 | 0.69592 | null | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000948 |
BRD-K17743125-001-08-4 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.148027 | 7.2626 | 0.617166 | 0.861413 | 2.062609 | 2.16476 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000948 |
BRD-K17894950-001-14-3 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.751423 | 0.52809 | 0.106176 | 0.890616 | 0.154332 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000948 |
BRD-K18961567-001-01-1 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.829843 | -0.730509 | -0.052636 | 0.87447 | 0.981947 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000948 |
BRD-K19540840-001-09-4 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.82949 | 5.491419 | 0.227454 | 0.867878 | 0.005422 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000948 |
BRD-K19796430-001-05-6 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 25.293009 | 0.964067 | -0.00244 | 1 | 46,968,811.608242 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000948 |
BRD-K22064724-001-01-8 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.066126 | 6.312991 | 0.665434 | 0.689177 | 0.395569 | 0.404559 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000948 |
BRD-K22822991-001-02-3 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.056338 | 0.073285 | -0.004165 | 1 | 0.012266 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000948 |
BRD-K23228615-001-02-8 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | -0.046173 | 0.453745 | 0.621984 | 0.597366 | 0.320739 | 0.264003 | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000948 |
BRD-K23984367-001-07-5 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.351068 | -2.863222 | -0.042577 | 0.983814 | 0.00061 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000948 |
BRD-K26026438-001-01-0 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.480661 | 5.988002 | 0.369406 | 0.676859 | 0.023854 | 0.041064 | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000948 |
BRD-K28822270-001-03-7 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.111022 | 0.43782 | 0.188101 | 0.64087 | 0.270136 | 0.479342 | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000948 |
BRD-K29905972-001-06-3 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.243394 | 0.174067 | -0.030974 | 1 | 4.662768 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000948 |
BRD-K30577245-001-05-0 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.210244 | 4.346789 | 0.305125 | 0.654283 | 0.008928 | 0.010122 | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000948 |
BRD-K31698212-001-02-9 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.109735 | 17.907578 | -0.058337 | 1 | 0.000949 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000948 |
BRD-K31928526-001-02-1 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.541096 | 0.063403 | -0.034587 | 0.897546 | 31,073,716.208033 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000948 |
BRD-K33379087-001-07-5 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.249556 | 12.469566 | 0.535198 | 0.84098 | 1.279102 | 1.352049 | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000948 |
BRD-K33610132-001-02-9 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.527335 | -0.797311 | 0.203413 | 1 | 0.075479 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000948 |
BRD-K33622447-066-01-9 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.825501 | 3.022629 | 0.066653 | 0.965706 | 1.486437 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000948 |
BRD-K35520305-001-16-9 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.016966 | -0.369082 | -0.010188 | 1 | 0.198605 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000948 |
BRD-K36627727-001-05-4 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.14819 | 0.066803 | -0.040072 | 1 | 0.000085 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000948 |
BRD-K36788280-001-01-2 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 29.54179 | 0.967626 | -0.068863 | 1 | 11,005,157.599297 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000948 |
BRD-K37379014-001-02-0 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.884912 | -3.253026 | -0.013501 | 0.9709 | 0.000111 | null | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000948 |
BRD-K38332599-001-01-3 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.345985 | 2.783515 | 0.499664 | 0.774102 | 0.350151 | 0.534533 | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000948 |
BRD-K38527262-300-01-0 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.408743 | 0.167093 | -0.002586 | 0.741965 | 0.360814 | null | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000948 |
BRD-K38852836-001-02-1 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.852838 | 3.613602 | 0.074625 | 0.918026 | 0.011247 | null | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000948 |
BRD-K39974922-001-04-3 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.534841 | 0.072706 | -0.068104 | 0.705559 | 0.00004 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000948 |
BRD-K41859756-001-06-8 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.140065 | -2.464978 | 0.117495 | 1 | 0.020979 | null | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000948 |
BRD-K42495768-001-01-7 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.161324 | 0.044268 | -0.012484 | 1 | 0.041052 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000948 |
BRD-K42805893-001-04-9 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.022942 | 1.08509 | 0.451703 | 0.782134 | 1.259767 | 1.315496 | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000948 |
BRD-K42828737-001-03-3 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | -0.671179 | 3.40011 | 0.21698 | 0.975014 | 11.414304 | 8.886325 | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000948 |
BRD-K42898655-001-01-8 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 36.683774 | 1.001272 | -0.025579 | 1 | 3,371,500.609477 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000948 |
BRD-K43389675-001-02-1 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | -0.013244 | 0.690423 | 0.598056 | 0.546346 | 0.134702 | 0.129697 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000948 |
BRD-K44227013-001-06-4 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.433646 | 1.739875 | 0.290581 | 0.845253 | 0.70941 | 2.264721 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000948 |
BRD-K44408410-001-17-6 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.705876 | 0.160518 | 0.022913 | 0.864164 | 0.212417 | null | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000948 |
BRD-K44827188-001-06-0 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.200648 | -0.479028 | 0.002143 | 1 | 0.352946 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000948 |
BRD-K46386702-001-02-1 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.675274 | 2.039999 | 0.095444 | 0.758128 | 0.007233 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000948 |
BRD-K49350383-001-14-5 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.779246 | 0.08049 | 0.047434 | 1 | 0.664223 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000948 |
BRD-K50010139-001-01-5 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | -0.112558 | 0.374223 | 0.19708 | 0.614411 | 0.650882 | 0.378333 | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000948 |
BRD-K50168500-001-07-9 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.44758 | 0.179713 | -0.005938 | 0.773954 | 0.684234 | null | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000948 |
BRD-K51313569-001-07-8 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.523642 | -0.340034 | 0.169041 | 1 | 0.061902 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000948 |
BRD-K51791723-003-01-7 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.041462 | 1.084089 | 0.572093 | 0.674062 | 0.378291 | 0.409736 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000948 |
BRD-K51967704-001-03-6 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 13.474727 | 0.357871 | -0.051109 | 1 | 309,807,999,894,642,500,000 | null | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000948 |
BRD-K52313696-001-12-3 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.263732 | -0.595523 | 0.046671 | 1 | 0.150192 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000948 |
BRD-K53414658-001-08-2 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.687608 | 0.633222 | 0.114425 | 0.865253 | 0.162597 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000948 |
BRD-K53972329-001-07-0 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.146418 | 0.199618 | -0.002807 | 1 | 0.724631 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000948 |
BRD-K54256913-001-08-7 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.729443 | -1.263212 | -0.013476 | 0.98705 | 0.00051 | null | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000948 |
BRD-K54955827-001-02-2 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.82609 | 0.132003 | 0.019442 | 0.906788 | 0.02525 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000948 |
BRD-K54997624-001-06-0 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.206466 | 0.284366 | 0.199751 | 0.632729 | 0.142917 | 0.930065 | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000948 |
BRD-K55187425-236-05-2 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.365734 | 12.252097 | 0.623968 | 0.682773 | 0.07799 | 0.086824 | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000948 |
BRD-K56343971-001-14-8 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.389295 | -0.062343 | 0.00668 | 1 | 0.054364 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000948 |
BRD-K56981171-001-02-8 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.661362 | 0.269293 | -0.089203 | 0.76863 | 0.00309 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000948 |
BRD-K57080016-001-15-9 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.12059 | 2.528324 | 0.068437 | 1 | 0.005148 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000948 |
BRD-K57169635-001-04-5 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.451573 | 1.82912 | -0.022583 | 0.860823 | 0.857158 | 3.071596 | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000948 |
BRD-K58435339-001-03-0 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.608481 | 0.346745 | 0.097718 | 0.803269 | 0.07541 | null | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000948 |
BRD-K58529924-001-01-5 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | -0.117326 | 1.704473 | 0.447258 | 0.908641 | 5.711438 | 5.047059 | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000948 |
BRD-K58550667-001-08-7 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.06672 | 7.461238 | 0.69842 | 0.686745 | 0.024051 | 0.024517 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000948 |
BRD-K59317601-001-05-5 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.314219 | 3.440912 | 0.723152 | 0.492126 | 0.007563 | 0.010084 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000948 |
BRD-K59369769-001-22-9 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 3.702162 | 0.330795 | 0.057818 | 1 | 883.570201 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000948 |
BRD-K60866521-001-07-1 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.214803 | -0.021248 | 0.00143 | 1 | 188,704,295.28252 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000948 |
BRD-K60997853-001-02-3 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.09479 | 5.863217 | 0.493719 | 0.946414 | 5.663682 | 5.870416 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000948 |
BRD-K61192372-001-08-9 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.884278 | -8.515871 | 0.122653 | 0.92531 | 0.320322 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000948 |
BRD-K62008436-001-23-9 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.229174 | 6.60458 | 0.578704 | 0.647874 | 0.00742 | 0.008142 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000948 |
BRD-K62196610-001-01-6 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.438322 | 4.483147 | 0.294711 | 0.79458 | 0.287467 | 0.45847 | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000948 |
BRD-K62200014-003-10-5 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 5.437028 | 0.932524 | -0.036915 | 1 | 550,706.932974 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000948 |
BRD-K62391742-001-09-7 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.987836 | -0.354987 | -0.000537 | 0.992823 | 0.276583 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000948 |
BRD-K62627508-001-01-5 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.124122 | 1.065723 | 0.720623 | 0.686314 | 0.316366 | 0.413496 | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000948 |
BRD-K63504947-001-14-7 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.708778 | 1.088396 | 0.17521 | 0.866522 | 0.11752 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000948 |
BRD-K63712959-001-01-8 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.253475 | -0.012194 | -0.000787 | 1 | 10.166825 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000948 |
BRD-K64052750-001-22-5 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.601902 | 4.743777 | 0.223541 | 0.890665 | 0.695776 | null | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000948 |
BRD-K64881305-001-03-7 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.187535 | 4.122347 | 0.812578 | 0.560158 | 0.052277 | 0.058592 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000948 |
BRD-K66175015-001-12-4 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | -0.210441 | 7.723587 | 0.716941 | 0.975421 | 8.477437 | 8.100478 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000948 |
BRD-K69001009-001-02-8 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.714504 | 0.058199 | -0.038024 | 0.853225 | 0.029428 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000948 |
BRD-K69694239-001-02-2 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.209376 | 7.046566 | 0.583848 | 0.766472 | 0.568989 | 0.614532 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000948 |
BRD-K69776681-001-03-8 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.386013 | 4.470471 | 0.753174 | 0.632106 | 0.029827 | 0.041519 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000948 |
BRD-K70301465-001-05-9 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.010552 | -0.26994 | -0.069896 | 1 | 5.077093 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000948 |
BRD-K70401845-001-15-7 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.442169 | 0.197988 | -0.15504 | 1 | 0.038809 | null | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000948 |
BRD-K73838513-003-05-5 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.914351 | 2.966889 | 0.022008 | 0.942757 | 0.015245 | null | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000948 |
BRD-K74514084-003-09-2 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.895995 | 0.649288 | 0.02687 | 0.946761 | 0.068879 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000948 |
BRD-K75009076-001-02-1 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.430351 | 2.12898 | 0.382753 | 0.841209 | 0.669565 | 1.69001 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000948 |
BRD-K76239644-001-02-6 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.168531 | 0.541356 | 0.362366 | 0.758922 | 0.903201 | 1.930011 | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000948 |
BRD-K76674262-001-03-3 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.444156 | 0.263162 | -0.134345 | 1 | 0.232506 | null | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000948 |
BRD-K76908866-001-07-6 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.551869 | 0.666226 | 0.306362 | 0.880639 | 1.000066 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000948 |
BRD-K77625799-001-07-7 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.649557 | -2.984578 | 0.036936 | 0.898925 | 0.01002 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000948 |
BRD-K78431006-001-15-1 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.01318 | -2.459675 | 0.000555 | 1 | 0.006447 | null | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000948 |
BRD-K79254416-001-21-8 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.293073 | 0.136823 | 0.020599 | 1 | 882.638931 | null | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000948 |
BRD-K81016934-001-02-0 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.907659 | 5.24127 | 0.005847 | 0.939155 | 0.016707 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000948 |
BRD-K81418486-001-44-2 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | -0.59566 | 4.038748 | 0.561004 | 0.967121 | 9.476487 | 7.803361 | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000948 |
BRD-K81473043-001-19-5 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.494317 | 5.818918 | 0.289143 | 0.763684 | 0.006701 | 0.014464 | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000948 |
BRD-K82135108-001-04-3 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.07516 | 4.482536 | 0.453193 | 0.60663 | 0.16119 | 0.167156 | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000948 |
BRD-K82746043-001-19-3 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.186976 | 0.659671 | 0.165644 | 0.36157 | 0.003183 | 0.006473 | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000948 |
BRD-K82818427-001-04-8 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 1.291671 | -0.117315 | 0.040169 | 1 | 0.021329 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000948 |
BRD-K83029223-001-01-3 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.146802 | 6.245277 | 0.701885 | 0.59396 | 0.006165 | 0.006518 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000948 |
BRD-K85402309-043-01-9 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.53636 | 0.374008 | 0.223257 | 0.76263 | 0.066462 | null | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000948 |
BRD-K85606544-001-09-1 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.809983 | 0.288726 | 0.000379 | 0.872614 | 0.004601 | null | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-000948 |
BRD-K86118762-001-01-8 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.514812 | -0.756826 | -0.040139 | 0.839185 | 0.013611 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000948 |
BRD-K86972824-001-01-4 | ACH-000948 | 2313287_STOMACH | MTS010 | 1 | 0.822177 | -0.142473 | -0.131123 | 0.860494 | 929.982087 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000948 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.